Temporal and dose-dependent relationships between in vivo B cell receptor-targeted proliferation and deletion-induced by a microbial B cell toxin

Journal of Immunology

Volumn 176, Issue 4, 2006, Pages 2262-2271

  Goodyear, Carl S ^a   Sugiyama, Fujimi ^a   Silverman, Gregg J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BACTERIAL TOXIN; IMMUNOGLOBULIN M; STAPHYLOCOCCUS PROTEIN A; SUPERANTIGEN; VIRULENCE FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; B LYMPHOCYTE; CONGENIC STRAIN; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOGLOBULIN PRODUCTION; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 32044471639     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.4.2262     Document Type: Article

References (37)

1. Nossal, G. J. 1995. Choices following antigen entry: antibody formation or immunologic tolerance? Annn. Rev. Immunol. 13: 1-27.
2. Silverman, G. J. 1997. B-cell superantigens. Immunol. Today 18: 379-386.
3. Sasso, E. H., G. J. Silverman, and M. Mannik. 1989. Human IgM molecules that bind staphylococcal protein A contain VHIII H chains. J. Immunol. 142: 2778-2783.
4. 2 that bind 10 staphylococcal protein A belong 10 the VHIII subgroup. J. Immunol. 147: 1877-1883.
5. Hillson, J. L., N. S. Karr, I. R. Oppliger, M. Mannik, and E. H. Sasso. 1993. The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A. J. Exp. Med. 178: 331-336.
6. Moks, T., L. Abrahmsen, B. Nilsson, U. Hellman, J. Sjoquist, and M. Uhlen. 1986. Staphylococcal protein A consists of live IgG-binding domains. Eur. J. Biochem. 156: 637-643.
7. Inganas, M., S. G. Johansson, and J. Sjoquist. 1981. Further characterization of the alternative protein-A interaction of immunoglobulins: demonstration of an Fc-binding fragment of protein A expressing the alternative reactivity. Scand. J. Immunol. 14: 379-388.
8. Graille, M., E. A. Stura, A. L. Corper, B. J. Sutton, M. J. Taussig, J. B. Charbonnier, and G. J. Silverman. 2000. Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc. Natl Acad. Sci. USA 97: 5399-5404.
9. H region surface. J. Immunol. 164: 4730-4741.
10. Silverman, G. J., M. Sasano, and S. B. Wormsley. 1993. Age-associated changes in binding of human B lymphocytes to a VH3-restricled unconventional bacterial antigen. J. Immunol 151: 5840-5855.
11. H families SI07 or J606 bind to protein A. J. Immunol 145: 2989-2993.
12. H III related 7183, J606 and S107 and DNA4 families commonly encode for binding to a bacterial B cell superantigen. Mol. Immunol. 36: 769-776.
13. H family-restricted staphylococcal B-cell superantigen. J. Immunol. 161: 5720-5732.
14. Silverman, G. J., S. P. Cary, D. C. Dwyer, L. Luo, R. Wagenknecht, and V. E. Curtiss. 2000. A B cell superantigen-induced persistent "hole" in the B-I repertoire. J. Exp. Med. 192: 87-98.
15. H-targeied apoptotic supraclonal B cell deletion by a staphylococcal toxin. J. Exp. Med. 197: 1125-1139.
16. Goodyear, C. S., and G. J. Silverman. 2004. Staphylococcal toxin induced preferential and prolonged in vivo deletion of innate-like B lymphocytes. Proc. Natl. Acad. Sci. USA 101: 11392-11397.
17. Marrack, P., P. Hugo, J. McCormack, and J. Kappler. 1993. Death and T cells. Immunol. Rev. 133: 119-129.
18. Hildeman, D. A., Y. Zhu, T. C. Mitchell, J. Kappler, and P. Marrack. 2002. Molecular mechanisms of activated T cell death in vivo. Curr. Opin. Immunol. 14: 354-359.
19. Hildeman, D. A., Y. Zhu, T. C. Mitchell, P. Bouillet, A. Strasser, J. Kappler, and P. Marrack. 2002. Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity 16: 759-767.
20. Taki, S., M. Meiering, and K. Rajewsky. 1993. Targeted insertion of a variable region gene into the immunoglobulin heavy chain locus. Science 262: 1268-1271.
21. Mardiney, M., 3rd, and H. L. Malech. 1996. Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy. Blood 87: 4049-4056.
22. Parish, C. R., and H. S. Warren. 2001. Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation. In Current Protocols In Immunology. J. E. Coligan, ed. John Wiley & Sons, New York, pp. 4.9.1-4.9.8.
23. Das, C., and J. J. Langone. 1987. Correlation between antitumor activity of protein A and in vivo formation of defined high molecular weight complexes with immunoglobulin G in BALB/c mice. Cancer Res. 47: 2002-2007.
24. Renno, T., A. Attinger, S. Locatelli, T. Bakker, S. Vacheron, and H. R. MacDonald. 1999. Cutting edge: apoptosis of superantigen-activated T cells occurs preferentially after a discrete number of cell divisions in vivo. J. Immunol. 162: 6312-6315.
25. Niiro, H., and E. A. Clark. 2002. Regulation of B-cell fate by antigen-receptor signals. Nat. Rev. Immunol. 2: 945-956.
26. Strasser, A. 2005. The role of BH3-only proteins in the immune system. Nat. Rev. Immunol. 5: 189-200.
27. Bouillet, P., J. F. Purton, D. I. Godfrey, L. C. Zhang, L. Coultas, H. Puthalakath, M. Pellegrini, S. Cory, J. M. Adams, and A. Strasser. 2002. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 415: 922-926.
28. Palmqvist, N., G. J. Silverman, E. Josefsson, and A. Tarkowski. 2005. Bacterial cell wall-expressed protein A triggers supraclonal B-cell responses upon in vivo infection with Staphylococcal aureus. Microbes Infect. 7: 1501-1511.
29. McKenney, D., K. L. Pouliot, Y. Wang, V. Murthy, M. Ulrich, G. Doring, J. C. Lee, D. A. Goldmann, and G. B. Pier. 1999. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 284: 1523-1527.
30. Silverman, G. J., C. S. Goodyear, and D. L. Siegel. 2005. On the mechanism of staphylococcal protein A immunomodulation. Transfusion 45: 274-280.
31. Balint, J., Jr., Y. Ikeda, J. J. Langone, W. T. Shearer, I. Daskal, K. Meek, G. Cook, J. Henry, and D. S. Terman. 1984. Tumoricidal response following perfusion over immobilized protein A: identification of immunoglobulin oligomers in serum after perfusion and their partial characterization. Cancer Res. 44: 734-743.
32. Sasso, E. H., C. Merrill, and D. T. Furst. 2000. Is release of staphylococcal protein A (SpA) during immunoadsorption therapy of rheumatoid arthritis related to clinical response? Arthritis Rheum. 43(Suppl.): 1342 (Abstr.).
33. Federal Drug Administration. 2002. Guidance for industry and reviewers: estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. U.S. Department of Health and Human Services, Rockville, MD.
34. Grimaldi, C. M., D. J. Michael, and B. Diamond. 2001. Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J. Immunol. 167: 1886-1890.
35. Roark, J. H., J. B. Bussel, D. B. Cines, and D. L. Siegel. 2002. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of elonal expansion and somatic mutation. Blood 100: 1388-1398.
36. Newkirk, M. M., J. Rauch, R. A. Mageed, R. Jefferis, D. N. Posnett, and G. J. Silverman. 1993. Restricted immunoglobulin variable region gene usage by hybridoma rheumatoid factors from patients with systemic lupus erythematosus and rheumatoid arthritis. Mol. Immunol. 30: 255-263.
37. Silverman, G. J., and S. Weisman. 2003. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 48: 1484-1492.